Metraipolis › archive › dc_2fbe438d4064
Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator — Europe PMC PMID:35259174
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/35259174
- DOI
- 10.1371/journal.pone.0264907
- License (as archived)
- CC0-1.0
- Archived
- 2026-10-31T08:04:31.847Z
- SHA-256 of the archived text
dc92cbb6998adb76c43ff9868514eec17211768d94a51117e717dd605b6ca971- Stable URL of this page
https://metraipolis.com/documento/dc_2fbe438d4064
How to cite
Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator — Europe PMC PMID:35259174 — Europe PMC (en), https://europepmc.org/article/MED/35259174 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_2fbe438d4064 (Metraipolis archive dc_2fbe438d4064, sha256 dc92cbb6998adb76c43ff9868514eec17211768d94a51117e717dd605b6ca971)
BibTeX
@misc{dc2fbe438d4064,
title = {Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator — Europe PMC PMID:35259174},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/35259174},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_2fbe438d4064; sha256 dc92cbb6998adb76c43ff9868514eec17211768d94a51117e717dd605b6ca971},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35259174. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Direct assessment of patient samples holds unprecedented potential in the treatment of cancer. Circulating tumor cells (CTCs) in liquid biopsies are a rapidly evolving source of primary cells in the clinic and are ideal candidates for functional assays to uncover real-time tumor information in real-time. However, a lack of routines allowing direct and active interrogation of CTCs directly from liquid biopsy samples represents a bottleneck for the translational use of liquid biopsies in clinical settings. To address this, we present a workflow for using a microfluidic vortex-assisted electroporation system designed for the functional assessment of CTCs purified from blood. Validation of this approach was assessed through drug response assays on wild-type (HCC827 wt) and gefitinib-resistant (HCC827 GR6) non-small cell lung cancer (NSCLC) cells. HCC827 cells trapped within microscale vortices were electroporated to sequentially deliver drug agents into the cytosol. Electroporation conditions facilitating multi-agent delivery were characterized for both cell lines using an automatic single-cell image fluorescence intensity algorithm. HCC827 GR6 cells spiked into the blood to emulate drug-resistant CTCs were able to be collected with high purity, demonstrating the ability of the device to minimize background cell impact for downstream sensitive cell assays. Using our proposed workflow, drug agent combinations to restore gefitinib sensitivity reflected the anticipated cytotoxic response. Taken together, these results represent a microfluidics multi-drug screening panel workflow that can enable functional interrogation of patient CTCs in situ, thereby accelerating the clinical standardization of liquid biopsies. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2022 (prima pubblicazione 2022-03-08). Identificativi: PMID 35259174 · PMCID PMC8903260 · DOI 10.1371/journal.pone.0264907. Descrittori MeSH principali: Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplastic Cells, Circulating. Pagina: https://europepmc.org/article/MED/35259174 — https://doi.org/10.1371/journal.pone.0264907. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-10-31T07:49:37.733Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.